| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | VACWR090 |
| Uniprot No | P07614 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-350aa |
| 氨基酸序列 | MNTRTDVTNDNIDKNPTKRGDKNIPGRNERFNDQNRFNNDIPKPKPRLQPNQPPKQDNKCREENGDFINIRLCAYEKEYCNDGYLSPAYYMLKQVDDEEMSCWSELSSLVRSRKAVGFPLLKAAKRISHGSMLYFEQFKNSKVVRLTPQVKCLNDTVIFQTVVILYSMYKRGIYSNEFCFDLVSIPRTNIVFSVNQLMFNICTDILVVLSICGNRLYRTNLPQSCYLNFIHGHETIARRGYEHSNYFFEWLIKNHISLLTKQTMDILKVKKKYAIGAPVNRLLEPGTLVYVPKEDYYFIGISLTDVSISDNVRVLFSTDGIVLEIEDFNIKHLFMAGEMFVRSQSSTIIV |
| 预测分子量 | 42.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于VACWR090重组蛋白的参考文献示例(注：由于VACWR090相关研究较为专业且可能非公开高频内容，以下为模拟示例，建议通过学术数据库核实具体文献)：
1. **文献名称**: *Expression and Purification of Recombinant VACWR090 Protein from Vaccinia Virus*
**作者**: Smith J, et al.
**摘要**: 本研究成功在大肠杆菌系统中表达并纯化了VACWR090重组蛋白，通过质谱和Western blot验证其正确性，为后续功能研究奠定基础。
2. **文献名称**: *Structural Characterization of VACWR090 and Its Role in Viral Assembly*
**作者**: Zhang L, et al.
**摘要**: 利用X射线晶体学解析了VACWR090蛋白的三维结构，发现其与病毒颗粒组装相关，敲除实验表明该蛋白缺失影响痘苗病毒复制效率。
3. **文献名称**: *Immunogenicity of VACWR090 Recombinant Protein in Animal Models*
**作者**: Lee C, et al.
**摘要**: 在小鼠模型中评估VACWR090重组蛋白的免疫原性，结果显示其可诱导特异性抗体及T细胞应答，提示其作为疫苗候选抗原的潜力。
4. **文献名称**: *Comparative Analysis of VACWR090 Homologs in Poxviruses*
**作者**: Garcia R, et al.
**摘要**: 通过比对痘病毒科成员中VACWR090同源蛋白的序列和功能，揭示其在病毒进化中的保守性及可能的宿主互作机制。
**注意**：以上文献信息为模拟生成，实际研究需通过PubMed、Web of Science等平台以“VACWR090 recombinant protein”或“VACWR090 vaccinia”为关键词检索最新成果。
VACWR090 is a recombinant protein derived from the vaccinia virus (VACV), a member of the *Poxviridae* family. The vaccinia virus, notably the Western Reserve (WR) strain, has been extensively studied due to its historical role as the live vaccine used in smallpox eradication. VACWR090 corresponds to the viral gene *VACWR090* (also annotated as *C9L* in some strains), which encodes a protein involved in modulating host immune responses. This gene is conserved across orthopoxviruses and is classified as a virulence factor, contributing to viral evasion of host defenses.
The VACWR090 protein is expressed during the early phase of viral infection and functions as an immunomodulator. It interacts with host signaling pathways, particularly those related to the nuclear factor kappa B (NF-κB) and interferon (IFN) systems, which are critical for antiviral immunity. By inhibiting these pathways, VACWR090 suppresses pro-inflammatory cytokine production and attenuates the host’s innate immune response, facilitating viral replication and spread. Structurally, the protein contains conserved domains characteristic of poxviral host range factors, including a putative transmembrane region and motifs associated with protein-protein interactions.
Recombinant VACWR090 is engineered for research applications, such as elucidating poxviral pathogenesis or screening antiviral compounds. Its production typically involves expression in bacterial or mammalian systems, followed by purification to study biochemical properties or antigenicity. Additionally, VACWR090 has been explored in vaccine development, either as a component of subunit vaccines or a target for neutralizing antibodies. Studies using knockout mutants have highlighted its importance in viral fitness *in vivo*, making it a potential candidate for attenuated vaccine design. Overall, VACWR090 serves as a valuable tool for understanding poxvirus-host interactions and advancing therapeutic strategies against poxviral infections.
在生物科技领域，蛋白研发与生产是前沿探索的关键支撑。艾普蒂作为行业内的创新者，凭借自身卓越的研发实力，每年能成功研发 1000 多种全新蛋白，在重组蛋白领域不断突破。 在重组蛋白生产过程中，艾普蒂积累了丰富且成熟的经验。从结构复杂的跨膜蛋白，到具有特定催化功能的酶、参与信号传导的激酶，再到用于免疫研究的病毒抗原，艾普蒂都能实现高效且稳定的生产。 这一成就离不开艾普蒂强大的技术平台。我们构建了多元化的重组蛋白表达系统，昆虫细胞、哺乳动物细胞以及原核蛋白表达系统协同运作。不同的表达系统各有优势，能够满足不同客户对重组蛋白的活性、产量、成本等多样化的需求，从而提供高品质、低成本的活性重组蛋白。 艾普蒂提供的不只是产品，更是从源头到终端的一站式解决方案。从最初的基因合成，精准地构建出符合要求的基因序列，到载体构建，为蛋白表达创造适宜的环境，再到蛋白质表达和纯化，每一个环节都严格把控。我们充分尊重客户的个性化需求，在表达 / 纯化标签的选择、表达宿主的确定等方面，为客户量身定制专属方案。 同时，艾普蒂还配备了多种纯化体系，能够应对不同特性蛋白的纯化需求。这种灵活性和专业性，极大地提高了蛋白表达和纯化的成功率，让客户的研究项目得以顺利推进，在生物科技的探索道路上助力每一位科研工作者迈向成功。
艾普蒂生物自主研发并建立综合性重组蛋白生产和抗体开发技术平台，包括： 哺乳动物细胞表达平台：利用哺乳动物细胞精准修饰蛋白，产出与天然蛋白相似的重组蛋白，用于药物研发、细胞治疗等。 杂交瘤开发平台：通过细胞融合筛选出稳定分泌单克隆抗体的杂交瘤细胞株，优化后的技术让抗体亲和力与特异性更高，应用于疾病诊断、免疫治疗等领域。 单 B 细胞筛选平台：FACS 用荧光标记和流式细胞仪快速分选特定 B 细胞；Beacon® 基于微流控技术，单细胞水平捕获、分析 B 细胞，挖掘抗体多样性，缩短开发周期。 凭借这些平台，艾普蒂生物为客户提供优质试剂和专业 CRO 技术服务，推动生物科技发展。
艾普蒂生物在重组蛋白和天然蛋白开发领域经验十分丰富，拥有超过 2 万种重组蛋白的开发案例。在四大重组蛋白表达平台的运用上，艾普蒂生物不仅经验老到，还积累了详实的成功案例。针对客户的工业化生产需求，我们能够定制并优化实验方案。通过小试探索、工艺放大以及条件优化等环节，对重组蛋白基因序列进行优化，全面探索多种条件，精准找出最契合客户需求的生产方法。 此外，公司还配备了自有下游验证平台，可对重组蛋白展开系统的质量检测与性能测试，涵盖蛋白互作检测、活性验证、内毒素验证等，全方位保障产品质量。 卡梅德生物同样重视蛋白工艺开发，确保生产出的蛋白质具备所需的纯度、稳定性与生物活性，这对于保障药物的安全性和有效性起着关键作用 ，与艾普蒂生物共同推动着行业的发展。
×
